| Proximal tubule bicarbonate reclamation |
1.85 |
1.09e-1 |
21/23 (91.3%) |
CA2;CA4;AQP1;...
|
| PPAR signaling pathway |
1.80 |
7.91e-2 |
66/74 (89.19%) |
PLIN1;ACSL1;PPARG;...
|
| Nicotine addiction |
1.78 |
6.26e-2 |
32/40 (80%) |
GABRE;GABRA1;SLC17A7;...
|
| Other types of O-glycan biosynthesis |
1.69 |
1.41e-1 |
29/47 (61.7%) |
RFNG;GALNT12;GALNT7;...
|
| Regulation of lipolysis in adipocytes |
1.64 |
1.86e-1 |
52/55 (94.55%) |
PLIN1;GNAS;FABP4;...
|
| Nitrogen metabolism |
1.63 |
1.66e-1 |
16/17 (94.12%) |
CA2;CA4;CA3;...
|
| Gastric acid secretion |
1.62 |
1.72e-1 |
63/76 (82.89%) |
GNAS;CA2;ATP1A2;...
|
| IL-17 signaling pathway |
1.62 |
1.51e-1 |
84/94 (89.36%) |
CXCL8;CCL2;LCN2;...
|
| Vasopressin-regulated water reabsorption |
1.60 |
1.60e-1 |
40/44 (90.91%) |
GNAS;RAB5B;DYNC1I1;...
|
| Pancreatic secretion |
1.60 |
1.44e-1 |
87/102 (85.29%) |
GNAS;CA2;PLA2G2A;...
|
| Dilated cardiomyopathy |
1.57 |
1.54e-1 |
86/96 (89.58%) |
GNAS;TPM2;ITGB4;...
|
| Adipocytokine signaling pathway |
1.55 |
1.76e-1 |
64/69 (92.75%) |
ACSL1;ADIPOQ;PCK1;...
|
| Bladder cancer |
1.54 |
1.81e-1 |
40/41 (97.56%) |
CXCL8;FGFR3;ERBB2;...
|
| Bile secretion |
1.54 |
1.71e-1 |
68/90 (75.56%) |
GNAS;CA2;AQP1;...
|
| Non-homologous end-joining |
1.53 |
1.61e-1 |
11/13 (84.62%) |
DNTT;RAD50;LIG4;...
|
| Mucin type O-glycan biosynthesis |
1.53 |
1.61e-1 |
20/36 (55.56%) |
GALNT12;GALNT7;GALNT1;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
1.48 |
2.28e-1 |
62/70 (88.57%) |
CXCL8;PAK1;MAPK10;...
|
| Steroid hormone biosynthesis |
1.46 |
2.65e-1 |
43/61 (70.49%) |
AKR1C2;AKR1C1;HSD17B6;...
|
| ECM-receptor interaction |
1.45 |
2.64e-1 |
80/88 (90.91%) |
ITGB4;COL6A1;COL4A5;...
|
| Proteoglycans in cancer |
1.44 |
2.65e-1 |
172/205 (83.9%) |
CAV2;PAK1;PLAUR;...
|
| Hypertrophic cardiomyopathy |
1.43 |
2.74e-1 |
81/90 (90%) |
TPM2;ITGB4;DMD;...
|
| Phenylalanine metabolism |
1.43 |
2.66e-1 |
14/17 (82.35%) |
MAOA;AOC3;ALDH3A1;...
|
| Fatty acid biosynthesis |
1.41 |
2.96e-1 |
16/18 (88.89%) |
ACSL1;FASN;ACSL3;...
|
| Central carbon metabolism in cancer |
1.41 |
2.92e-1 |
67/70 (95.71%) |
FGFR3;HIF1A;LDHB;...
|
| AMPK signaling pathway |
1.40 |
2.84e-1 |
106/120 (88.33%) |
PPARG;ADIPOQ;SCD;...
|
| Focal adhesion |
1.38 |
3.06e-1 |
180/201 (89.55%) |
CAV2;PAK1;ITGB4;...
|
| alpha-Linolenic acid metabolism |
1.38 |
3.02e-1 |
17/25 (68%) |
PLA2G2A;PLAAT3;ACOX1;...
|
| Tight junction |
1.38 |
2.98e-1 |
130/169 (76.92%) |
AMOTL2;MYH11;CLDN10;...
|
| Thiamine metabolism |
1.38 |
2.90e-1 |
12/15 (80%) |
AK4;ALPP;AK5;...
|
| Cocaine addiction |
1.38 |
2.81e-1 |
42/49 (85.71%) |
GNAS;MAOA;CDK5R1;...
|
| RNA transport |
-1.14 |
6.25e-1 |
128/186 (68.82%) |
EIF2B4;FMR1;EIF4A1;...
|
| Acute myeloid leukemia |
-1.16 |
6.09e-1 |
66/67 (98.51%) |
PIK3R1;TCF7L1;RUNX1;...
|
| Coronavirus disease |
-1.16 |
6.21e-1 |
215/232 (92.67%) |
MASP2;MAPK14;RSL24D1;...
|
| Vitamin digestion and absorption |
-1.17 |
6.05e-1 |
17/24 (70.83%) |
APOA4;SCARB1;APOB;...
|
| Hematopoietic cell lineage |
-1.17 |
6.12e-1 |
90/99 (90.91%) |
GP5;IL1R2;GYPA;...
|
| Spinocerebellar ataxia |
-1.17 |
6.06e-1 |
128/143 (89.51%) |
PSMD7;ADRM1;AFG3L2;...
|
| Staphylococcus aureus infection |
-1.18 |
6.15e-1 |
72/95 (75.79%) |
MBL2;DEFA5;HLA-DOA;...
|
| C-type lectin receptor signaling pathway |
-1.19 |
5.83e-1 |
93/104 (89.42%) |
STAT1;BCL10;MAPKAPK2;...
|
| Metabolism of xenobiotics by cytochrome P450 |
-1.20 |
5.85e-1 |
49/77 (63.64%) |
ADH7;GSTO1;GSTT2;...
|
| Glutathione metabolism |
-1.20 |
5.95e-1 |
43/57 (75.44%) |
ANPEP;GSTO1;GSTT2;...
|
| Lysosome |
-1.20 |
5.90e-1 |
115/128 (89.84%) |
PLA2G15;CTSW;TPP1;...
|
| Allograft rejection |
-1.20 |
6.01e-1 |
32/38 (84.21%) |
HLA-F;FASLG;IL10;...
|
| Drug metabolism |
-1.21 |
6.11e-1 |
78/151 (51.66%) |
GUSB;CYP2C8;ADH7;...
|
| Pertussis |
-1.21 |
6.06e-1 |
64/76 (84.21%) |
LY96;JUN;MYD88;...
|
| Tryptophan metabolism |
-1.21 |
6.17e-1 |
35/42 (83.33%) |
KYNU;TDO2;DHTKD1;...
|
| Various types of N-glycan biosynthesis |
-1.25 |
6.19e-1 |
26/39 (66.67%) |
MAN1A2;DDOST;CHST8;...
|
| PD-L1 expression and PD-1 checkpoint pathway in cancer |
-1.28 |
6.07e-1 |
79/89 (88.76%) |
HRAS;JUN;MAP2K3;...
|
| Synthesis and degradation of ketone bodies |
-1.28 |
6.21e-1 |
9/10 (90%) |
BDH1;ACAT1
|
| Cortisol synthesis and secretion |
-1.32 |
6.18e-1 |
58/65 (89.23%) |
ADCY8;ADCY9;AGT;...
|
| Thyroid cancer |
-1.33 |
6.08e-1 |
36/37 (97.3%) |
RXRA;CCDC6;TCF7L1;...
|
| Inflammatory bowel disease |
-1.35 |
5.91e-1 |
58/65 (89.23%) |
IL5;IFNGR2;HLA-DRB1;...
|
| Cytosolic DNA-sensing pathway |
-1.35 |
6.13e-1 |
52/63 (82.54%) |
DDX58;POLR3C;POLR2F;...
|
| Legionellosis |
-1.40 |
6.00e-1 |
51/57 (89.47%) |
ARF1;HSPD1;HSPA1A;...
|
| Aminoacyl-tRNA biosynthesis |
-1.42 |
5.96e-1 |
15/66 (22.73%) |
TARS2;LARS2;WARS2;...
|
| Fat digestion and absorption |
-1.43 |
5.93e-1 |
35/43 (81.4%) |
CD36;PLA2G1B;AGPAT2;...
|
| Valine, leucine and isoleucine degradation |
-1.57 |
3.24e-1 |
42/48 (87.5%) |
AUH;ACADM;PCCB;...
|
| Cholesterol metabolism |
-1.60 |
2.89e-1 |
44/50 (88%) |
SOAT2;CETP;CD36;...
|
| RNA polymerase |
-1.71 |
1.35e-1 |
23/31 (74.19%) |
POLR3C;POLR2F;POLR3K;...
|
| Ribosome biogenesis in eukaryotes |
-1.74 |
1.47e-1 |
52/108 (48.15%) |
CSNK2B;BMS1;RCL1;...
|
| Ribosome |
-1.80 |
1.82e-1 |
113/158 (71.52%) |
RPS28;RPL4;RPS11;...
|
